HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial

HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial

Background Irinotecan is used as second-line treatment in advanced gastric or gastroesophageal junction (G/GEJ) cancer. The role of anti-programmed death-1 (PD-1) antibody plus irinotecan, in this setting and population is unclear.Methods This multicenter, open-label, single-arm, phase II trial was...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ning Li, Shu Zhang, Yan Song, Jing Huang, Qun Li, Xinjun Liang, Qingxia Fan, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Xiaofei Wang, Yiwei Dou
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2020-10-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/8/2/e001279.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Gradient material Pd-PdHx
by: M. V. Goltsova, et al.
Published: (2018-10-01)

Gastroesophageal junction adenocarcinoma. A case report
by: Marcos Félix Osorio Pagola, et al.
Published: (2010-12-01)

Case report: Chemotherapy plus sintilimab for the treatment of gastroesophageal junction hepatoid adenocarcinoma with liver metastasis: a case study with literature review
by: Genlin Lu, et al.
Published: (2025-01-01)

Efficacy of Neoadjuvant Chemotherapy DOX and XELOX Regimens for Patients with Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
by: Yuan Tian, et al.
Published: (2021-01-01)

Cost-effectiveness analysis of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma: perspectives from the United States and China
by: Wenwang Lang, et al.
Published: (2024-11-01)

Health-related quality of life with bemarituzumab plus mFOLFOX6 in patients with FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer
by: Z.A. Wainberg, et al.
Published: (2024-12-01)

Perioperative tislelizumab plus chemotherapy for locally advanced gastroesophageal junction adenocarcinoma (NEOSUMMIT-03): a prospective, nonrandomized, open-label, phase 2 trial
by: Run-Cong Nie, et al.
Published: (2025-02-01)

First-line treatment with zolbetuximab plus CAPOX for ClDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a cost-effectiveness analysis
by: Jianying Lei, et al.
Published: (2024-11-01)

Synergistic Effects of Simvastatin and Irinotecan against Colon Cancer Cells with or without Irinotecan Resistance
by: Hyun Joo Jang, et al.
Published: (2016-01-01)

Canadian Consensus Recommendations for Predictive Biomarker Testing in Gastric and Gastroesophageal Junction Adenocarcinoma
by: Christine Brezden-Masley, et al.
Published: (2024-12-01)

Kyoto International Consensus Report on Anatomy, Pathophysiology and Clinical Significance of the Gastroesophageal Junction
by: A. A. Sheptulin, et al.
Published: (2023-12-01)

The Efficacy of Ramucirumab in the Treatment of Gastric or Gastroesophageal Junction Cancer: A Meta-Analysis of RCTs
by: Hongqiong Yang, et al.
Published: (2021-01-01)

Case report: Patients with positive HER-2 amplification locally advanced gastroesophageal junction cancer achieved pathologic complete response with the addition of pembrolizumab to chemotherapy plus trastuzumab as neoadjuvant therapy
by: Huanhuan Li, et al.
Published: (2025-02-01)

Irinotecan Plus S-1 Followed by Hepatectomy for a Patient with Initially Unresectable Colorectal Liver Metastases, Who Showed Severe Drug Rash with Oxaliplatin Plus 5-FU and Leucovorin (FOLFOX)
by: Hiroyuki Komori, et al.
Published: (2014-01-01)

Baseline (derived) neutrophil-lymphocyte ratio associated with survival in gastroesophageal junction or gastric cancer treated with ICIs
by: Chengyang Yu, et al.
Published: (2025-01-01)

Xylene biodegradation by free and immobilized Sphingomonas paucimobilis strain TY4-HX on graphene oxide
by: Hossein Mohammadpour, et al.
Published: (2018-12-01)

Rifaximin alleviates irinotecan-induced diarrhea in mice model
by: Chengyi Huang, et al.
Published: (2024-12-01)

ST8-t008-SCCmec IV methicillin-resistant Staphylococcus aureus in retail fresh cheese
by: Carolina Chaves, et al.
Published: (2024-11-01)

Feasibility trial of STRONG: A digital intervention to improve nutritional management for individuals with esophageal and gastroesophageal junction cancer
by: Yu Chen Lin, et al.
Published: (2025-02-01)

A rare case of synchronous management of gastroesophageal junction adenocarcinoma and renal cell carcinoma: is it just another oesophagectomy?
by: Natasha Hasemaki, et al.
Published: (2024-09-01)

Management and Reconstruction of a Gastroesophageal Junction Adenocarcinoma Patient Three Years after Pancreaticoduodenectomy: A Surgical Puzzle
by: Dionysios Dellaportas, et al.
Published: (2016-01-01)

The epidemiological trends and predictions of esophageal squamous cell carcinoma and gastroesophageal junction carcinoma: an Australian population-based study
by: Shalika Bohingamu Mudiyanselage, et al.
Published: (2024-12-01)

Transarterial Infusion Chemotherapy and Embolization for Patients With Unresectable Advanced Cancer of Stomach or Gastroesophageal Junction: A Retrospective Study
by: Lingqiang Min, et al.
Published: (2024-11-01)

Isolation of a more aggressive GVI-1 genotype strain HX of the avian infectious bronchitis virus
by: Fan Yang, et al.
Published: (2024-12-01)

Acute Immune-Mediated Thrombocytopenia due to Oxaliplatin and Irinotecan Therapy
by: Eric L. Tam, et al.
Published: (2019-01-01)

Optimizing HX-Group Compositions Using <i>C</i>++: A Computational Approach to Dihedral Group Hyperstructures
by: Andromeda Pătraşcu Sonea, et al.
Published: (2024-11-01)

008. Massive Teratoma Attached to The Inferior Vena Cava and Abdominal Aorta in Pediatric Patient: A Case Report
by: Natario Natario, et al.
Published: (2024-10-01)

Updated cost-effectiveness analysis of tislelizumab in combination with chemotherapy for the first-line treatment of advanced gastric cancer or gastroesophageal junction adenocarcinoma
by: Lei Xu, et al.
Published: (2024-12-01)

Panitumumab versus cetuximab in combination with irinotecan in refractory metastatic colorectal cancer
by: Maria Ignez Freitas Melro Braghiroli, et al.
Published: (2024-01-01)

Preclinical pharmacology characterization of HX009, a novel PD1 x CD47 Bi-specific antibody
by: Hang Ke, et al.
Published: (2024-11-01)

Resilience of Spanish Firms: a comparative analysis of large and small businesses in the face of 008 financial crisis and COVID-19
by: Jose Sevilla, et al.
Published: (2025-01-01)

A conceptual model for advanced/metastatic gastric or gastroesophageal junction cancer: a review of qualitative studies and results from patient interviews
by: France Ginchereau Sowell, et al.
Published: (2025-01-01)

Experimental Study of Irinotecan Induced Side Effects on Digestive and Immune System of Mice
by: Liya LIU, et al.
Published: (2018-04-01)

Oxyresveratrol Alleviates Irinotecan-Induced Diarrhea and Enhances Antitumor Effects in Colorectal Cancer
by: Yang X, et al.
Published: (2024-12-01)

Induced Opening of the Gastroesophageal Junction Occurs at a Lower Gastric Pressure in Gerd Patients and in Hiatal Hernia Subjects than in Normal Control Subjects
by: Anil Vegesna, et al.
Published: (2010-01-01)

沃尔什-哈达玛变换A=HX的分量奇偶性的简单证明及其推论
by: 汪芳铭
Published: (1985-01-01)

Modulation of Apoptosis and ER Stress Markers in Hepatocellular Carcinoma Cells by Irinotecan, Hesperidin, and Piperine
by: Serkan Sen, et al.
Published: (2024-11-01)

Gastroesophageal reflux.
by: Yanet Hidalgo Marrero, et al.
Published: (2005-12-01)

Comparative efficacy of programmed death ligand 1 inhibition and chemotherapy in advanced gastric or gastroesophageal junction cancer with combined positive score – a meta-analysis
by: Zakari Shaibu, et al.
Published: (2024-10-01)

Comment on “Impact of the Surgical Approach for Neoadjuvantly Treated Gastroesophageal Junction Type II Tumors: A Multinational, High-Volume Center Retrospective Cohort Analysis”
by: Arnar B. Ingason, MD, PhD, et al.
Published: (2024-06-01)